A novel theranostic probe [111In]In-DO3A-NHS-nimotuzumab in glioma xenograft
A novel theranostic probe [111In]In-DO3A-NHS-nimotuzumab in glioma xenograft
Untitled
NL E4-0-C-REF - ROW
PDF) Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair